Payment overview · 2025
General Payments
$592.63
29 reported records · 14 companies
Healthcare provider profile · identity verified
Robert M Sexton, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MURFREESBORO, TN · NPI 1952656829
Verified facts
What the public records show
CMS Open Payments records show Robert M Sexton, FNP received $592.63 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $111.68 | 18.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $100.58 | 17.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.77 | 14.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.83 | 8.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.72 | 7.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.42 | 7.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.25 | 4.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.71 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.69 | 3.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.33 | 3.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.86 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.74 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.79 | 2.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.26 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $592.63 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $100.58 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $86.77 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.04 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.04 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $53.64 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.72 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.42 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 48 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 350 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 110 |
| Lisinopril | Lisinopril | 317 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 101 |
| Metformin Hcl | Metformin Hcl | 240 | 74 |
| Gabapentin | Gabapentin | 225 | 67 |
| Omeprazole | Omeprazole | 223 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 67 |
| Losartan Potassium | Losartan Potassium | 186 | 63 |
| Azithromycin | Azithromycin | 185 | 121 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 62 |
| Glimepiride | Glimepiride | 167 | 55 |
| Methylprednisolone | Methylprednisolone | 167 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 61 |
| Simvastatin | Simvastatin | 152 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 57 |
| Meloxicam | Meloxicam | 149 | 56 |
| Furosemide | Furosemide | 142 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 45 |
| Carvedilol | Carvedilol | 125 | 42 |
| Alprazolam | Alprazolam | 120 | 25 |
| Prednisone | Prednisone | 111 | 79 |
| Trazodone Hcl | Trazodone Hcl | 105 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 36 |
| Sertraline Hcl | Sertraline Hcl | 99 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 34 |
| Potassium Chloride | Potassium Chloride | 91 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 24 |
| Finasteride | Finasteride | 84 | 28 |
| Famotidine | Famotidine | 83 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 26 |
| Montelukast Sodium | Montelukast Sodium | 77 | 21 |
| Allopurinol | Allopurinol | 76 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 29 |
| Metformin Hcl Er | Metformin Hcl | 75 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 24 |
| Spironolactone | Spironolactone | 63 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 21 |
| Eliquis | Apixaban | 60 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 19 |
| Pregabalin | Pregabalin | 54 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 22 |
| Estradiol | Estradiol | 51 | 12 |
| Clonidine Hcl | Clonidine Hcl | 50 | 16 |
| Clonazepam | Clonazepam | 48 | 13 |
| Ozempic | Semaglutide | 48 | 14 |
| Celecoxib | Celecoxib | 47 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 36 |
| Diazepam | Diazepam | 47 | 13 |
| Donepezil Hcl | Donepezil Hcl | 47 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Lovastatin | Lovastatin | 45 | 14 |
| Atenolol | Atenolol | 41 | 13 |
| Fluconazole | Fluconazole | 40 | 21 |
| Lorazepam | Lorazepam | 40 | 12 |
| Buspirone Hcl | Buspirone Hcl | 38 | 15 |
| Cefdinir | Cefdinir | 38 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 11 |
| Jardiance | Empagliflozin | 38 | 12 |
| Chlorthalidone | Chlorthalidone | 37 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 14 |
| Valsartan | Valsartan | 36 | 11 |
| Bupropion Xl | Bupropion Hcl | 35 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 15 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 13 |
| Baclofen | Baclofen | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 12 |
| Synthroid | Levothyroxine Sodium | 30 | 11 |
| Colchicine | Colchicine | 29 | suppressed |
| Movantik | Naloxegol Oxalate | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Cephalexin | Cephalexin | 18 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Benzonatate | Benzonatate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $592.63 · 29 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, General - Erectile Dysfunction, Kerendia, LEQVIO, MOUNJARO, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error